Silvana Saracchini

695 total citations
32 papers, 341 citations indexed

About

Silvana Saracchini is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Silvana Saracchini has authored 32 papers receiving a total of 341 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 15 papers in Cancer Research and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Silvana Saracchini's work include Cancer Treatment and Pharmacology (15 papers), Breast Cancer Treatment Studies (13 papers) and HER2/EGFR in Cancer Research (9 papers). Silvana Saracchini is often cited by papers focused on Cancer Treatment and Pharmacology (15 papers), Breast Cancer Treatment Studies (13 papers) and HER2/EGFR in Cancer Research (9 papers). Silvana Saracchini collaborates with scholars based in Italy, Germany and Spain. Silvana Saracchini's co-authors include Diana Crivellari, Enzo Galligioni, Massimo Gion, S. Monfardini, Roberto Sorio, Andrea Freschi, I. Robieux, R. Mione, Giulio Vignati and Antonio Fortunato and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

Silvana Saracchini

29 papers receiving 329 citations

Peers

Silvana Saracchini

ONCOL

PRM

PFM

Erion Dobi France

Eriseld Krasniqi Italy

Federico Castiglione Italy

Aurélie Ferru France

David Coeffic France

Laura Demurtas Italy

Αναστασία Κατσιαμπούρα United States

L Anselmi Italy

Giuseppe Colantuoni Italy

S. Sugarman United States

Erion Dobi France

Silvana Saracchini

217 ×0.9

ONCOL

111 ×0.9

147 ×2.0

PRM

74 ×1.1

28 ×0.8

PFM

Citations per year, relative to Silvana Saracchini Silvana Saracchini (= 1×) peers Erion Dobi

Countries citing papers authored by Silvana Saracchini

Since Specialization

Citations

This map shows the geographic impact of Silvana Saracchini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silvana Saracchini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silvana Saracchini more than expected).

Fields of papers citing papers by Silvana Saracchini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silvana Saracchini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silvana Saracchini. The network helps show where Silvana Saracchini may publish in the future.

Co-authorship network of co-authors of Silvana Saracchini

This figure shows the co-authorship network connecting the top 25 collaborators of Silvana Saracchini. A scholar is included among the top collaborators of Silvana Saracchini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silvana Saracchini. Silvana Saracchini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schettini, Francesco, Silvana Saracchini, Serena Corsetti, et al.. (2024). Prediction of response to neoadjuvant chemotherapy by MammaTyper® across breast cancer subtypes: A retrospective cross-sectional study. The Breast. 76. 103753–103753. 1 indexed citations

Saracchini, Silvana, Serena Corsetti, Ralph M. Wirtz, et al.. (2020). Abstract P1-10-23: Prediction of pathological complete response (pCR) upon neoadjuvant chemotherapy by MammaTyper® pCR score. Cancer Research. 80(4_Supplement). P1–10.

Pelizzari, Giacomo, Lorenzo Gerratana, Debora Basile, et al.. (2019). Role of anthracyclines in neoadjuvant anti-HER2 regimens for HER2+ breast cancer (BC): A network meta-analysis (NMA).. Journal of Clinical Oncology. 37(15_suppl). 577–577.

Lumachi, Franco, Alessandro Del Conte, Silvana Saracchini, et al.. (2017). P2.03a-031 Metronomic Oral Vinorelbine as First-Line Treatment in Elderly (>65 Year) Patients with Advanced NSCLC. Journal of Thoracic Oncology. 12(1). S907–S907. 1 indexed citations

Mustacchi, Giorgio, Fabio Puglisi, Diana Crivellari, et al.. (2015). Observational Study on Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer Patients. Future Oncology. 11(10). 1493–1500. 9 indexed citations

Saracchini, Silvana, Luisa Foltran, S. Sulfaro, et al.. (2013). Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification. The Breast. 22(6). 1101–1107. 19 indexed citations

Clavarezza, Matteo, Monica Turazza, Enrico Aitini, et al.. (2013). Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer. The Breast. 22(4). 470–475. 11 indexed citations

Amadori, D., Carlo Milandri, G. Comella, et al.. (2011). A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer. European Journal of Cancer. 47(14). 2091–2098. 20 indexed citations

Smith, Ian, Jean‐Yves Pierga, Laura Biganzoli, et al.. (2011). Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial. Breast Cancer Research and Treatment. 130(1). 133–143. 41 indexed citations

10.

Amadori, D., Giulio Gasparini, Andrea Ardizzoni, et al.. (2009). Phase II study of liposomal doxorubicin (Myocet®), docetaxel and trastuzumab combination as first line treatment of patients with her-2/neu positive locally advanced or metastatic breast cancer.. Cancer Research. 69(2_Supplement). 3149–3149. 1 indexed citations

11.

Mastro, Lucia Del, Matteo Clavarezza, D. Amadori, et al.. (2007). Once-weekly epoetin beta treatment in anemic patients with breast cancer receiving chemotherapy: Interim analysis of a multicenter, single arm study. Journal of Clinical Oncology. 25(18_suppl). 19605–19605. 1 indexed citations

12.

Conté, Pierfranco, Sara Donati, Alessandra Gennari, et al.. (2005). Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study. British Journal of Cancer. 93(4). 406–411. 14 indexed citations

13.

Tumolo, Salvatore, et al.. (2001). Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer. Lung Cancer. 34. 37–46. 1 indexed citations

14.

Sorio, Roberto, I. Robieux, Enzo Galligioni, et al.. (1997). Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. European Journal of Cancer. 33(2). 301–303. 59 indexed citations

15.

Gion, Massimo, R. Mione, Gianni Cappelli, et al.. (1995). Tumor markers in breast cancer follow-up: A potentially useful parameter still awaiting definitive assessment. Annals of Oncology. 6. S31–S35. 23 indexed citations

16.

Gion, Massimo, R. Mione, Giulio Vignati, et al.. (1993). Variability of Tumor Markers in the Follow-Up of Patients Radically Resected for Breast Cancer. Tumor Biology. 14(6). 325–333. 11 indexed citations

17.

Figoli, F., Enzo Galligioni, Diana Crivellari, et al.. (1991). Evaluation of Two Consecutive Regimens in Advanced Gastric Cancer. Cancer Investigation. 9(3). 257–262. 6 indexed citations

18.

Franceschi, Silvia, Diego Serraino, Silvana Saracchini, Emanuela Vaccher, & Umberto Tirelli. (1989). Risk factors for human immunodeficiency virus (HIV) infection among homosexual and bisexual men in a region at low risk for AIDS: the northeastern part of Italy. AIDS and Related Syndromes Study Group.. PubMed. 37(2). 103–8. 1 indexed citations

19.

Tirelli, Umberto, Emanuela Vaccher, Diego Serraino, et al.. (1988). Comparison of presenting clinical and laboratory findings of patients with persistent generalized lymphadenopathy (PGL) syndrome and malignant lymphoma (ML).. PubMed. 72(6). 563–5. 8 indexed citations

20.

Veronesi, Andrea, Enzo Galligioni, Re G, et al.. (1986). Combination chemotherapy with fluorouracil, adriamycin, cis-Platinum and VM-26 in advanced transitional cell carcinoma of the urinary tract. European Journal of Cancer and Clinical Oncology. 22(12). 1457–1460. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact